Abstract
Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.
Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
Keywords: ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), TNF-inhibitors, tocilizumab.
Current Pharmaceutical Biotechnology
Title:Biologics in Inflammatory Immune-mediated Systemic Diseases
Volume: 18 Issue: 12
Author(s): Gianluca Moroncini*, Giovanni Calogera, Devis Benfaremo and Armando Gabrielli
Affiliation:
- Clinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Universita Politecnica delle Marche, Ancona,Italy
Keywords: ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), TNF-inhibitors, tocilizumab.
Abstract: Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.
Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
Export Options
About this article
Cite this article as:
Moroncini Gianluca*, Calogera Giovanni , Benfaremo Devis and Gabrielli Armando , Biologics in Inflammatory Immune-mediated Systemic Diseases, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666171226152448
DOI https://dx.doi.org/10.2174/1389201019666171226152448 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Topical Nanocarriers for Treatment of Psoriasis: An Overview
Current Pharmaceutical Design Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy Somatic Genome Variations in Health and Disease
Current Genomics Erythropoietin Directly Affects Human Macrophage Functionality
Current Pharmaceutical Biotechnology Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Modifying TNF alpha for Therapeutic Use A Perspective on the TNF Receptor System
Mini-Reviews in Medicinal Chemistry IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Mucosal Immunity - Basic Principles, Ontogeny, Cystic Fibrosis and Mucosal Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus
Current Pharmaceutical Design Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Current and Potential Agents for the Treatment of Alopecia Areata
Current Pharmaceutical Design Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry